Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “HIV 2 Infection”

647 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 647 results

Early research (Phase 1)Study completedNCT02277600
What this trial is testing

Antiretroviral Drug-Drug Interaction Study in Healthy Volunteers (DDI)

Who this might be right for
Infection, Human Immunodeficiency Virus
ViiV Healthcare 32
Testing effectiveness (Phase 2)Study completedNCT00000811
What this trial is testing

Compare Different Drugs Used to Prevent Serious Bacterial Infections in HIV-Positive Children

Who this might be right for
Bacterial InfectionsPneumonia, Pneumocystis CariniiHIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 690
Large-scale testing (Phase 3)WithdrawnNCT00381017
What this trial is testing

Effects of Low-dose Maintenance Peg Interferon Alfa-2b Therapy Versus Supportive Care in Patients With Cirrhotic Hepatitis C With HIV (Study P04371)

Who this might be right for
Hepatitis CLiver CirrhosisHIV Infections
Merck Sharp & Dohme LLC
Testing effectiveness (Phase 2)Study completedNCT01605890
What this trial is testing

Trial Evaluating a First Line Combination Therapy With Raltegravir, Emtricitabine and Tenofovir in HIV-2 Infected Patients

Who this might be right for
HIV-2 Infection
ANRS, Emerging Infectious Diseases 30
Early research (Phase 1)Study completedNCT01336829
What this trial is testing

TMC125IFD1001 - Drug-Drug Interaction of Etravirine With Telaprevir and TMC278 With Telaprevir.

Who this might be right for
Hepatitis CHIV
Tibotec Pharmaceuticals, Ireland 33
Early research (Phase 1)Study completedNCT00703586
What this trial is testing

Study of the Antiviral and Immunological Effects of Intensification of Suppressive Antiretroviral Therapy With Maraviroc

Who this might be right for
HIV Infections
Rockefeller University 8
Early research (Phase 1)Study completedNCT00000986
What this trial is testing

The Safety and Effectiveness of Interleukin-2 Plus Zidovudine in Patients With AIDS or AIDS Related Complex

Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 18
Testing effectiveness (Phase 2)Study completedNCT00530777
What this trial is testing

HSV-2 Suppression to Reduce Maternal HIV-1 RNA Levels During Pregnancy and Breastfeeding

Who this might be right for
HIV InfectionsHerpes Simplex
University of Washington 148
Testing effectiveness (Phase 2)Study completedNCT03982277
What this trial is testing

Safety and Efficacy of High Dose Rifampicin in Tuberculosis (TB)-HIV Co-infected Patients on Efavirenz- or Dolutegravir-based Antiretroviral Therapy

Who this might be right for
Tuberculosis
Makerere University 130
Early research (Phase 1)Study completedNCT04827134
What this trial is testing

A Food-effect Study of the Pediatric Dispersible Tablet Formulations of TRIUMEQ® and DOVATO® in Healthy Adult Participants

Who this might be right for
HIV Infections
ViiV Healthcare 33
Early research (Phase 1)Study completedNCT00000972
What this trial is testing

A Phase I Clinical Trial to Evaluate: Part A. The Safety of MTP-PE/MF59 Adjuvant Emulsion. Part B. The Safety and Immunogenicity of Env 2-3, a Yeast Derived Recombinant Envelope Protein of Human Immunodeficiency Virus-1, in Combination With MTP-PE/MF59

Who this might be right for
HIV InfectionsHIV Seronegativity
National Institute of Allergy and Infectious Diseases (NIAID) 64
Testing effectiveness (Phase 2)Ended earlyNCT00385567
What this trial is testing

A Trial of PEHRG214 in HIV-Infected Patients

Who this might be right for
HIV Infections
Virionyx Corporation Limited 70
Testing effectiveness (Phase 2)Study completedNCT00251537
What this trial is testing

A Pilot Study of LTB4 in HIV-1 Infected Adults

Who this might be right for
HIV Infections
LTB4 Sweden AB 40
Early research (Phase 1)Study completedNCT00574600
What this trial is testing

Safety of and Immune Response to Two HIV Vaccines: SAAVI DNA-C2 Boosted With SAAVIMVA-C, in HIV-Negative Adults

Who this might be right for
HIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 48
Testing effectiveness (Phase 2)Study completedNCT02225665
What this trial is testing

Repeat Doses of SB-728mR-T After Cyclophosphamide Conditioning in HIV-Infected Subjects on HAART

Who this might be right for
Human Immunodeficiency Virus (HIV)
Sangamo Therapeutics 8
Large-scale testing (Phase 3)Study completedNCT05917509
What this trial is testing

Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy

Who this might be right for
HIV Infections
ViiV Healthcare 171
Early research (Phase 1)Study completedNCT00000739
What this trial is testing

Comparison of Two Dosage Regimens of Oral Dapsone for Prophylaxis of Pneumocystis Carinii Pneumonia in Pediatric HIV Infection

Who this might be right for
Pneumonia, Pneumocystis CariniiHIV Infections
National Institute of Allergy and Infectious Diseases (NIAID) 96
Large-scale testing (Phase 3)Study completedNCT01419899
What this trial is testing

Increasing Viral Testing in the Emergency Department

Who this might be right for
Drug UseHIVHepatitis C
Rhode Island Hospital 398
Post-approval studies (Phase 4)Looking for participantsNCT07138144
What this trial is testing

Efficacy, Safety, and ToLerability of Switching to A Two-Drug Regimen With DTG/3TC Compared to Maintaining A Three-Drug REgimen With BIC/FTC/TAF or DTG/3TC/ABC in ViroLogically SupprEssed PeopLe Living With HIV After 24 and 48 Weeks of Follow-Up

Who this might be right for
HIV Infections
José Antonio Mata Marín 156
Early research (Phase 1)Study completedNCT03307915
What this trial is testing

2 Different Regimens of Tetravalent Ad26.Mos4.HIV Prime Followed by Boost With Modified Vaccinia Ankara (MVA)-Mosaic OR Ad26.Mos4.HIV Plus a Combination of Mosaic and Clade C gp140 Protein in Human Immunodeficiency Virus (HIV) Type 1 Infected Adults on Suppressive Antiretroviral Treatment

Who this might be right for
Human Immunodeficiency Virus
Janssen Vaccines & Prevention B.V. 25
Next Page